The Journal is Indexed in
3 - Adalimumab and infliximab of use inflammatory markers, cytokines and matrix metalloproteinase-3 levels effect in patient with rheumatoid arthritis and ankylosing spondylitis
Sibel Serin, Yıldız Okuturlar, Ayşe Gözkaman, Belkıs Nihan Coşkun, Vehbi Yağız, Kamil Dilek
Objective: We aimed to assess adalimumab(ADA) and infliximab(IFX) efficacy on the patients of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) by using erithrocyte sedimentation rate (ESR), C-reactive protein (CRP), interferon gamma (IF-?), interleukin-1 beta (IL-1ß), interleukin 6 (IL- 6), matrix metalloproteinase 3 (MMP-3).
Material and Method: Sixteen RA, 15 AS patients were enrolled to this study. ADA was used on the half of RA patients , IFX was used on the other half randomly. ADA was used on 7 AS patients and IFX was used on 8 AS patients randomly too. Blood samples were taken at the weeks of 0, 1, 4 and 12. ESR and CRP were calculated at the same time with controls. Blood samples were hidden at the -20°C to evaluate after.
Results: There wasnt any significant difference between the groups of RA and AS patients in terms of ESH and CRP levels (p>0.05). IF-? was found lower on both patient groups and IL-6 and IL-1ß were not included statistical analysis due to the wide range of values. MMP-3 levels was found correlated with ESR and CRP levels in both treatment and patient groups. MMP -3 was more supressed at ADA treated group on AS patients according to the IFX group on AS patients significantly (p<0.05).
Conclusion: MMP-3 was significantly more depressed on ADA treated group of the AS patients according to IFX treated group. We think many similar studies that include more patients needs to be done to say ADAs better efficacy than in AS patients. It can be said that MMP-3 is a stable marker to determine the activity of chronic inflammatory diseases and monitoring response to therapy according to the cytokines.
Keywords: Rheumatoid arthritis, ankylosing spondylitis, adalimmumab, infliximab
To read full article click